NZ625621A - Treatment for diabetes in patients inappropriate for metformin therapy - Google Patents
Treatment for diabetes in patients inappropriate for metformin therapyInfo
- Publication number
- NZ625621A NZ625621A NZ625621A NZ62562109A NZ625621A NZ 625621 A NZ625621 A NZ 625621A NZ 625621 A NZ625621 A NZ 625621A NZ 62562109 A NZ62562109 A NZ 62562109A NZ 625621 A NZ625621 A NZ 625621A
- Authority
- NZ
- New Zealand
- Prior art keywords
- patients
- dpp
- medicament
- inhibitor
- methyl
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003105 metformin Drugs 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 208000010444 Acidosis Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 206010017605 Galactose intolerance Diseases 0.000 abstract 1
- 208000027472 Galactosemias Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 abstract 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract 1
- 206010027417 Metabolic acidosis Diseases 0.000 abstract 1
- 206010062237 Renal impairment Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract 1
- 230000018044 dehydration Effects 0.000 abstract 1
- 238000006297 dehydration reaction Methods 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000008085 renal dysfunction Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8662008P | 2008-08-06 | 2008-08-06 | |
| EP08161989 | 2008-08-07 | ||
| US10591508P | 2008-10-16 | 2008-10-16 | |
| EP08166827 | 2008-10-16 | ||
| NZ60396109 | 2009-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ625621A true NZ625621A (en) | 2015-11-27 |
Family
ID=55405604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ625621A NZ625621A (en) | 2008-08-06 | 2009-08-05 | Treatment for diabetes in patients inappropriate for metformin therapy |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ625621A (en) |
-
2009
- 2009-08-05 NZ NZ625621A patent/NZ625621A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ590787A (en) | DPP-4 inhibitors for treating diabetes in patients showing contraindication against metformin therapy | |
| NZ605207A (en) | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | |
| NZ625577A (en) | Therapeutic uses of pharmaceutical compositions | |
| JP5906086B2 (en) | Purine derivatives for use in the treatment of FAB-related diseases | |
| JP4643760B2 (en) | A pharmaceutical comprising a combination or combination of a DPP-IV inhibitor and another antidiabetic agent | |
| JP2023011007A5 (en) | ||
| TWI618537B (en) | Diabetes therapy | |
| US10034877B2 (en) | Treatment for diabetes in patients inappropriate for metformin therapy | |
| JP2016518438A5 (en) | ||
| NZ593754A (en) | Dpp-iv inhibitors for treatment of diabetes in paediatric patients | |
| NZ609765A (en) | Uses of dpp-iv inhibitors | |
| EP2854812A1 (en) | A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada | |
| NZ625621A (en) | Treatment for diabetes in patients inappropriate for metformin therapy | |
| US11911388B2 (en) | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | |
| US20240148737A1 (en) | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug | |
| EA044961B1 (en) | TREATMENT OF DIABETES | |
| EA041228B1 (en) | TREATMENT OF DIABETES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 AUG 2016 BY SPRUSON + FERGUSON Effective date: 20160329 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 AUG 2017 BY DENNEMEYER + CO. Effective date: 20160722 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 AUG 2018 BY DENNEMEYER + CO Effective date: 20170726 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 AUG 2019 BY DENNEMEYER + CO Effective date: 20180802 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 AUG 2020 BY DENNEMEYER + CO. Effective date: 20190719 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 AUG 2021 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20200727 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 AUG 2022 BY DENNEMEYER + CO. Effective date: 20210726 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 AUG 2023 BY DENNEMEYER + CO. SARL. Effective date: 20220725 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 AUG 2024 BY DENNEMEYER + CO. SARL Effective date: 20230724 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 AUG 2025 BY DENNEMEYER ET CO Effective date: 20240729 |